JMT101 Combined With Mitoxantrone Liposome for Nasopharyngeal Cancer

NCT06892431 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

150

Enrollment

INDUSTRY

Sponsor class

Conditions

Recurrent or Metastatic Nasopharyngeal Cancer
Patients Who Have Experienced Treatment Failure at Least Second-line Chemotherapy

Interventions

DRUG: Mitoxantrone Hydrochloride Liposome
DRUG: JMT101 injection
DRUG: Capecitabine
DRUG: Docetaxel injection
DRUG: Gemcitabine hydrochloride for injection

Sponsor

Shanghai JMT-Bio Inc.